Pharmacokinetics of Piperacillin and Meropenem in ICU Patients

Karolinska University Hospital

Status: Unknown

Conditions: Antibiotic Pharmacokinetics

Treatments: Drug: Piperacillin/tazobactam, Meropenem

Study type: Observational

Funder types: Other

Identifiers

NCT05134298

K 2018-6443

Details and patient eligibility

About

The purpose of the study is to characterize the pharmacokinetics of meropenem and piperacillin in ICU-patients at the time of the first dose administration and to contrast that with the same measurements obtained in the same patient 2-3 days later during the course of ICU treatment.

Enrollment: 50 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Patient being treated in one of the participating ICUs and planned to recieve treatment with meropenem or piperacillin.

Exclusion Criteria (fullfilling any exlusion criteria means that patient cannot be included in the study):

• Not possible to retrospectively ask the patient or next of kin for consent to take part in the study or patient or next-of-kin not providing consent.
• Not posisble to obtain and process blood samples as specified by protocol.
• Ongoing renal replacement therapy.
• Patient having received the same antibiotic within the previous 96 h.

Trial design

50 participants in 1 patient group

Study Kohort

Description:

As specified by study population, inclusion and exclusion criteria

Treatment:

Drug: Piperacillin/tazobactam, Meropenem